Exact Sciences Corporation (NASDAQ:EXAS) Surges 27% Yet Its Low P/S Is No Reason For Excitement
May 07
Have your own idea? Try our Stock Screener
U.S. Biotech Industry Analysis
UpdatedMay 08, 2025
DataAggregated Company Financials
Companies568
- 7D-7.7%
- 3M-13.5%
- 1Y-13.5%
- YTD-8.8%
Over the last 7 days, the Biotech industry has dropped 6.3%, driven by Vertex Pharmaceuticals declining 11%. The industry has fallen 14% in the last year. Earnings are forecast to grow by 24% annually.
Industry Valuation and Performance
Has the U.S. Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Thu, 08 May 2025 | US$890.3b | US$155.1b | -US$25,574,283,733.68 | 18.6x | -34.8x | 5.7x |
| Sat, 05 Apr 2025 | US$774.2b | US$118.6b | -US$37,107,737,767.73 | 20.1x | -20.9x | 6.5x |
| Mon, 03 Mar 2025 | US$850.8b | US$118.9b | -US$37,265,127,499.97 | 17x | -22.8x | 7.2x |
| Wed, 29 Jan 2025 | US$991.6b | US$149.5b | -US$26,314,079,099.96 | 17.5x | -37.7x | 6.6x |
| Fri, 27 Dec 2024 | US$990.4b | US$149.9b | -US$26,370,197,964.77 | 16.1x | -37.6x | 6.6x |
| Sun, 24 Nov 2024 | US$1.0t | US$150.0b | -US$26,558,578,256.44 | 16.6x | -38.3x | 6.8x |
| Tue, 22 Oct 2024 | US$908.0b | US$113.1b | -US$36,019,658,167.43 | 21.3x | -25.2x | 8x |
| Thu, 19 Sep 2024 | US$925.6b | US$113.2b | -US$35,972,157,840.12 | 22.6x | -25.7x | 8.2x |
| Sat, 17 Aug 2024 | US$882.4b | US$113.2b | -US$35,765,976,434.68 | 22.3x | -24.7x | 7.8x |
| Mon, 15 Jul 2024 | US$1.2t | US$164.5b | -US$28,105,214,748.90 | 29.4x | -42.5x | 7.3x |
| Wed, 12 Jun 2024 | US$1.2t | US$164.5b | -US$26,795,949,828.09 | 28.2x | -43.3x | 7.1x |
| Fri, 10 May 2024 | US$1.1t | US$164.8b | -US$26,733,495,747.45 | 23.2x | -41.9x | 6.8x |
| Sun, 07 Apr 2024 | US$1.1t | US$164.4b | -US$23,431,530,428.03 | 21.3x | -48.2x | 6.9x |
| Tue, 05 Mar 2024 | US$1.2t | US$167.9b | -US$21,298,840,556.03 | 15.9x | -56x | 7.1x |
| Thu, 01 Feb 2024 | US$1.4t | US$204.7b | -US$22,672,999,235.00 | 17.8x | -63.6x | 7x |
| Sat, 30 Dec 2023 | US$1.4t | US$204.9b | -US$22,199,644,413.00 | 19.8x | -62.9x | 6.8x |
| Mon, 27 Nov 2023 | US$1.2t | US$204.8b | -US$22,013,452,568.00 | 18.6x | -55.7x | 6x |
| Wed, 25 Oct 2023 | US$1.2t | US$207.5b | -US$13,040,888,319.00 | 16.2x | -93x | 5.8x |
| Fri, 22 Sep 2023 | US$1.3t | US$207.5b | -US$12,875,537,971.00 | 17.1x | -98.4x | 6.1x |
| Sun, 20 Aug 2023 | US$1.3t | US$207.6b | -US$12,372,676,716.00 | 17.6x | -102.2x | 6.1x |
| Tue, 18 Jul 2023 | US$1.1t | US$186.7b | -US$15,958,556,257.00 | 12.9x | -71.1x | 6.1x |
| Thu, 15 Jun 2023 | US$1.2t | US$186.1b | -US$15,929,018,280.00 | 11.7x | -72.3x | 6.2x |
| Sat, 13 May 2023 | US$1.2t | US$191.7b | -US$12,347,110,804.00 | 13.8x | -93.5x | 6x |
| Mon, 10 Apr 2023 | US$1.2t | US$198.3b | -US$3,291,225,770.00 | 14x | -353.5x | 5.9x |
| Wed, 08 Mar 2023 | US$1.1t | US$198.7b | -US$5,119,400,088.00 | 15.9x | -221.2x | 5.7x |
| Fri, 03 Feb 2023 | US$1.2t | US$203.9b | US$1.8b | 14.9x | 642.4x | 5.7x |
| Sun, 01 Jan 2023 | US$1.1t | US$203.5b | US$1.7b | 14.3x | 663.5x | 5.6x |
| Tue, 29 Nov 2022 | US$1.1t | US$202.3b | US$1.3b | 14.7x | 841.8x | 5.5x |
| Thu, 27 Oct 2022 | US$1.1t | US$206.5b | US$6.4b | 14.1x | 171.7x | 5.3x |
| Sat, 24 Sep 2022 | US$1.0t | US$206.0b | US$5.6b | 13.9x | 182.3x | 4.9x |
| Mon, 22 Aug 2022 | US$1.1t | US$206.4b | US$7.3b | 16x | 147.7x | 5.2x |
| Wed, 20 Jul 2022 | US$1.1t | US$211.3b | US$10.6b | 17.2x | 102.8x | 5.2x |
| Fri, 17 Jun 2022 | US$922.8b | US$212.3b | US$11.0b | 14.6x | 84x | 4.3x |
| Sun, 15 May 2022 | US$993.9b | US$212.0b | US$10.6b | 15.6x | 94.1x | 4.7x |
Price to Earnings Ratio
94.1x
Current Industry PE
- Investors are relatively neutral on the American Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady.
- The industry is trading close to its 3-year average PS ratio of 6.3x.
Past Earnings Growth
- Total earnings for the Biotechs industry have declined over the last three years, with the industry now making a loss overall.
- Revenues have also declined 10% per year, which is driving profits down.
Industry Trends
Which industries have driven the changes within the U.S. Healthcare industry?
| US Market | 1.22% | |
| Healthcare | -3.95% | |
| Biotech | -7.72% | |
| Biotech | -7.72% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| ALNY Alnylam Pharmaceuticals | US$276.55 | 5.1% +US$2.0b | 81.6% | PS15.4x | |
| EXAS Exact Sciences | US$53.28 | 16.7% +US$1.4b | -10.4% | PS3.6x | |
| NBIX Neurocrine Biosciences | US$121.61 | 12.9% +US$1.4b | -12.5% | PE39.4x | |
| NTRA Natera | US$160.10 | 6.1% +US$1.2b | 67.4% | PS12.8x | |
| HALO Halozyme Therapeutics | US$70.14 | 14.2% +US$1.1b | 67.0% | PE17.8x |
